BMO Capital commented on Celgene (Nasdaq: CELG) following news that that the Journal of Clinical Oncology has published the results ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE